Pharmaessentia Corp.
- Biotech or pharma, therapeutic R&D
Our flagship product ropeginterferon alfa-2b (P1101) is a novel long-acting, mono-pegylated proline interferon developed using our PEGylation technology platform.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}